



[Home](#) / [Investors](#) / [Press Releases](#)

Insmmed to Host Investor and Analyst Event on May 8, 2023

— *The Future of Rare at Insmmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More*—

BRIDGEWATER, N.J., April 24, 2023 [/PRNewswire/](#) -- Insmmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host an investor and analyst event on Monday, May 8, 2023. The event, titled "The Future of Rare at Insmmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More," will take place from 8:00 a.m. to 12:00 p.m. ET in New York and will be simultaneously webcast.

The agenda will include a deep dive into Insmmed's early-stage research programs. Members of the management team will be joined by Insmmed's Deimmunized by Design, gene therapy, and protein manufacturing team leaders to unveil the platforms and capabilities that the company believes will generate at least six new investigational new drug applications by 2025.

A live webcast will be available on the company's website at www.insmed.com. A replay of the event will be accessible approximately 30 minutes after its completion. A copy of the presentation materials and webcast will be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmmed

Insmmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
Insmmed
(646) 812-4030
bryan.dunn@insmed.com

Eleanor Barisser
Associate Director, Investor Relations
Insmmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmmed
(732) 718-3621
amanda.fahey@insmed.com